drugset / Trial / NCT01965626

A Multicenter Randomized Open-label Study of Oseltamivir Combined With HD-DEX Versus HD-DEX in the Management of ITP

NCT01965626

Phase 2 Completed 96 enrolled Shandong University
RandomizedParallel-groupOpen-labelTreatment

Summary

Oseltamivirphosphate is hydrolysed to its active metabolite-the free carboxylate of oseltamivir. Oseltamivir is a neuraminidase inhibitor, serving as a competitive inhibitor of the activity of the viral neuraminidase (NA) enzyme upon sialic acid, found on glycoproteins on the surface of platelets. By blocking the activity of the enzyme, oseltamivir may prevent platelet destruction in liver.The project was undertaking by Qilu Hospital of Shandong University and other 4 well-known hospitals in China. In order to report the efficacy and safety of oseltamivirphosphate combined with high-dose dexamethasone for the treatment of immune thrombocytopenia (ITP) with high platelet desialylation level, compared to high-dose dexamethasone therapy.

Timeline

Start
2016-02-01
Primary completion
2018-05
Completion
2019-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Dexamethasone Small molecule 40 mg Oral
Comparator Oseltamivir Small molecule 75 mg Oral

Indications